The present invention relates to the development of the cationic progesterone compounds as a novel anti-tumor agent. The present invention provides a method for the preparation of novel series of progesterone derivatives. The invention also provides information related to highly selective anti-cancer activities of these compounds in wide range of cancer cell irrespective of their progesterone receptor status. Thus, the presently disclosed cationic progesterone compounds offer a viable option as anti-cancer therapeutics.
本发明涉及阳离子
孕酮化合物作为新型
抗肿瘤药物的开发。 本发明提供了一系列新型
黄体酮衍
生物的制备方法。 本发明还提供了与这些化合物在多种癌细胞中的高选择性抗癌活性相关的信息,而不论其
孕酮受体状态如何。 因此,目前公开的阳离子
孕酮化合物为抗癌疗法提供了一种可行的选择。